ProQR Therapeutics N.V.
NASDAQ:PRQR
Overview | Financials
Company Name | ProQR Therapeutics N.V. |
Symbol | PRQR |
Currency | USD |
Price | 2.68 |
Market Cap | 276,586,720 |
Dividend Yield | 0% |
52-week-range | 1.61 - 4.62 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel Anton de Boer |
Website | https://www.proqr.com |
An error occurred while fetching data.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD